Review of the current treatments for leishmaniases

References

• DesjeuxPLeishmaniasis: current situation and new perspectivesComp Immunol Microbiol Infect Dis200427530531815225981
   PubMed Web of Science ®Google Scholar
• FauldeMSchraderJHeylGAmirihMDifferences in transmission seasons as an epidemiological tool for characterization of anthroponotic and zoonotic cutaneous leishmaniasis in northern AfghanistanActa Trop2008105213113818068684
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO)Control of Leishmaniases: report of a meeting of the WHO Expert CommitteeGenevaWHO2010
   Google Scholar
• BanulsALHideMPrugnolleFLeishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humansAdv Parasitol200764110917499100
   PubMed Web of Science ®Google Scholar
• GotoHLindosoJACurrent diagnosis and treatment of cutaneous and mucocutaneous leishmaniasisExpert Rev Anti Infect Ther20108441943320377337
   PubMed Web of Science ®Google Scholar
• ArevaloJRamirezLAdauiVInfluence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasisJ Infect Dis2007195121846185117492601
   PubMed Web of Science ®Google Scholar
• RomeroGAGuerraMVPaesMGMacedoVOComparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniateAm J Trop Med Hyg200165545646511716098
   PubMed Web of Science ®Google Scholar
• SeifertKStructures, targets and recent approaches in anti-leishmanial drug discovery and developmentOpen Med Chem J20115313921629509
   PubMedGoogle Scholar
• MarsdenPDJonesTCClinical manifestations, diagnosis and treatment of cutaneous leishmaniasisChangK-PBrayRSAmsterdamElsevier Science1985
   Google Scholar
• CroftSLSeifertKYardleyVCurrent scenario of drug development for leishmaniasisIndian J Med Res2006123339941016778319
   PubMed Web of Science ®Google Scholar
• EllisMBernsenRAli-ZadehHA safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic feverJ Med Microbiol200958Pt 111474148519589901
   PubMed Web of Science ®Google Scholar
• MarsdenPDPersonal experience with diagnostic and therapeutic aspects of human Leishmania (Viannia) braziliensis in Tres BracosMemorias do Instituto Oswaldo Cruz19948934854877476237
   PubMed Web of Science ®Google Scholar
• BermanJDHuman leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 yearsClin Infect Dis19972446847039145744
   PubMed Web of Science ®Google Scholar
• MaaroufMde KouchkovskyYBrownSPetitPXRobert-GeroMIn vivo interference of paromomycin with mitochondrial activity of LeishmaniaExp Cell Res199723223393489168810
   PubMed Web of Science ®Google Scholar
• MitropoulosPKonidasPDurkin-KonidasMNew World cutaneous leishmaniasis: updated review of current and future diagnosis and treatmentJ Am Acad Dermatol201063230932220303613
   PubMed Web of Science ®Google Scholar
• ZijlstraEEMusaAMKhalilEAel-HassanIMel-HassanAMPost-kala-azar dermal leishmaniasisLancet Infect Dis200332879812560194
   PubMed Web of Science ®Google Scholar
• MurrayHWBermanJDDaviesCRSaraviaNGAdvances in leishmaniasisLancet200536694961561157716257344
   PubMed Web of Science ®Google Scholar
• Brazil. Ministry of HealthSecretary of Health Surveillance. Visceral leishmaniasis, clinical recommendations for the reduction of mortality2nd edBrasíliaMinistry of Health782009 Available at: portal.saude.gov.br/portal/arquivos/.../lv_reducao_letalidade_web.pdf
   Google Scholar
• AlvarJCroftSOlliaroPChemotherapy in the treatment and control of leishmaniasisAdv Parasitol20066122327416735166
   PubMed Web of Science ®Google Scholar
• SundarSDrug resistance in Indian visceral leishmaniasisTrop Med Int Health200161184985411703838
   PubMed Web of Science ®Google Scholar
• BernCAdler-MooreJBerenguerJLiposomal amphotericin B for the treatment of visceral leishmaniasisClin Infect Dis200643791792416941377
   PubMed Web of Science ®Google Scholar
• SundarSChakravartyJAgarwalDRaiMMurrayHWSingle-dose liposomal amphotericin B for visceral leishmaniasis in IndiaN Engl J Med2010362650451220147716
   PubMed Web of Science ®Google Scholar
• BermanJDDevelopment of miltefosine for the leishmaniasesMini Rev Med Chem20066214515116472183
   PubMed Web of Science ®Google Scholar
• CroftSLSundarSFairlambAHDrug resistance in leishmaniasisClin Microbiol Rev200619111112616418526
   PubMed Web of Science ®Google Scholar
• SundarSChakravartyJParomomycin in the treatment of leishmaniasisExpert Opin Investig Drugs2008175787794
   PubMed Web of Science ®Google Scholar
• DavidsonRNden BoerMRitmeijerKParomomycinTrans R Soc Trop Med Hyg2009103765366018947845
   PubMed Web of Science ®Google Scholar
• HailuAMusaAWasunnaMGeographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trialPLoS Negl Trop Dis2010410e70921049059
   PubMed Web of Science ®Google Scholar
• GonzalezUPinartMReveizLAlvarJInterventions for Old World cutaneous leishmaniasisCochrane Database Syst Rev20084CD00506718843677
   PubMed Web of Science ®Google Scholar
• SotoJMToledoJTGutierrezPTreatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot studyAm J Trop Med Hyg200266214715112135285
   PubMed Web of Science ®Google Scholar
• DaviesCRReithingerRCampbell-LendrumDFeliciangeliDBorgesRRodriguezNThe epidemiology and control of leishmaniasis in Andean countriesCad Saude Publica200016492595011175518
   PubMedGoogle Scholar
• Oliveira-NetoMPSchubachAMattosMGoncalves-CostaSCPirmezCA low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years)Am J Trop Med Hyg19975766516559430521
   PubMed Web of Science ®Google Scholar
• PalaciosROsorioLEGrajalewLFOchoaMTTreatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia speciesAm J Trop Med Hyg2001643–418719311442216
   PubMed Web of Science ®Google Scholar
• RochaPNAlmeidaRPBacellarODown-regulation of Th1 type of response in early human American cutaneous leishmaniasisJ Infect Dis199918051731173410515843
   PubMed Web of Science ®Google Scholar
• SantosJBde JesusARMachadoPRAntimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous Leishmaniasis ulcers: a randomized, double-blind, placebo-controlled studyJ Infect Dis2004190101793179615499535
   PubMed Web of Science ®Google Scholar
• CostaJMValeKCFrancaFSpontaneous healing of leishmaniasis caused by Leishmania viannia braziliensis in cutaneous lesionsRev Soc Bras Med Trop19902342052082133585
   PubMedGoogle Scholar
• AmatoVSRabelloARotondo-SilvaASuccessful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patientsActa tropica200492212713215350864
   PubMed Web of Science ®Google Scholar
• BrownMNoursadeghiMBoyleJDavidsonRNSuccessful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasisBr J Dermatol2005153120320516029352
   PubMed Web of Science ®Google Scholar
• ParadisiACapizziRZampettiAAtypical multifocal cutaneous leishmaniasis in an immunocompetent patient treated by liposomal amphotericin BJ Infect2005515e261e26415936088
   PubMedGoogle Scholar
• RappCImbertPDarieHLiposomal amphotericin B treatment of cutaneous leishmaniasis contracted in Djibouti and resistant to meglumine antimoniateBull Soc Pathol Exot200396320921114582297
   PubMedGoogle Scholar
• YardleyVCroftSLA comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasisInt J Antimicrob Agents200013424324810755238
   PubMed Web of Science ®Google Scholar
• LightburnEMorandJJMeynardJBManagement of American cutaneous leishmaniasis. Outcome apropos of 326 cases treated with high-dose pentamidine isethionateMed Trop (Mars)2003631354412891748
   PubMedGoogle Scholar
• AndersenEMCruz-SaldarriagaMLlanos-CuentasAComparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasisAm J Trop Med Hyg200572213313715741547
   PubMed Web of Science ®Google Scholar
• SotoJReaJBalderramaMEfficacy of miltefosine for Bolivian cutaneous leishmaniasisAm J Trop Med Hyg200878221021118256415
   PubMed Web of Science ®Google Scholar
• SotoJAranaBAToledoJMiltefosine for new world cutaneous leishmaniasisClin Infect Dis20043891266127215127339
   PubMed Web of Science ®Google Scholar
• JolliffeDSCutaneous leishmaniasis from Belize – treatment with ketoconazoleClin Exp Dermatol198611162683708895
   PubMed Web of Science ®Google Scholar
• FrankeEDWignallFSCruzMEEfficacy and toxicity of sodium stibogluconate for mucosal leishmaniasisAnn Intern Med1990113129349402173461
   PubMed Web of Science ®Google Scholar
• AmatoVSTuonFFImamuraRAbegao de CamargoRDuarteMINetoVAMucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in BrazilJ Eur Acad Dermatol Venereol20092391026103419453817
   PubMed Web of Science ®Google Scholar
• Oliveira-NetoMPMattosMPirmezCMucosal leishmaniasis (“espundia”) responsive to low dose of N-methyl glucamine (Glucantime) in Rio de Janeiro, BrazilRev Inst Med Trop Sao Paulo200042632132511136518
   PubMedGoogle Scholar
• de Oliveira-NetoMPMattos MdaSSuccessful therapeutic response of resistant cases of mucocutaneous leishmaniasis to a very low dose of antimonyRev Soc Bras Med Trop200639437637817119754
   PubMed Web of Science ®Google Scholar
• AmatoVSTuonFFBachaHANetoVANicodemoACMucosal leishmaniasis. Current scenario and prospects for treatmentActa Trop200810511917884002
   PubMed Web of Science ®Google Scholar
• AmatoVSTuonFFCamargoRASouzaRMSantosCRNicodemoACCan we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis?Am J Trop Med Hyg201185581881922049033
   PubMed Web of Science ®Google Scholar
• SotoJToledoJValdaLTreatment of Bolivian mucosal leishmaniasis with miltefosineClin Infect Dis200744335035617205440
   PubMed Web of Science ®Google Scholar
• SotoJReaJValderramaMEfficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in BoliviaAm J Trop Med Hyg200981338738919706901
   PubMed Web of Science ®Google Scholar
• Brazil. Ministry of HealthSecretary of Health Surveillance. Guideline on Surveillance of American Tegumentary Leishmaniasis2nd edBrasíliaMinistry of Health1802010 Available at: portal.saude.gov.br/portal/arquivos/pdf/manual_lta_2ed.pdf
   Google Scholar
• CruzINietoJMorenoJCanavateCDesjeuxPAlvarJLeishmania/ HIV co-infections in the second decadeIndian J Med Res2006123335738816778317
   PubMed Web of Science ®Google Scholar
• AlvarJCanavateCGutierrez-SolarBLeishmania and human immunodeficiency virus coinfection: the first 10 yearsClin Microbiol Rev19971022983199105756
   PubMed Web of Science ®Google Scholar
• RabelloAOrsiniMDischJLeishmania/HIV co-infection in Brazil: an appraisalAnn Trop Med Parasitol200397Suppl 1172814678630
   PubMedGoogle Scholar
• AlvarJAparicioPAseffaAThe relationship between leishmaniasis and AIDS: the second 10 yearsClin Microbiol Rev2008212334359 table of contents18400800
   PubMed Web of Science ®Google Scholar
• RitmeijerKter HorstRChaneSLimited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalenceClin Infect Dis20115312e152e15822016502
   PubMed Web of Science ®Google Scholar
• HailuWWeldegebrealTHurissaZSafety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infectionTrans R Soc Trop Med Hyg20101041170671220870258
   PubMed Web of Science ®Google Scholar
• RitmeijerKDejenieAAssefaYA comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infectionClin Infect Dis200643335736416804852
   PubMed Web of Science ®Google Scholar
• SinhaPKvan GriensvenJPandeyKLiposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, IndiaClin Infect Dis2011537e91e9821890763
   PubMed Web of Science ®Google Scholar
• den BoerMLAlvarJDavidsonRNRitmeijerKBalasegaramMDevelopments in the treatment of visceral leishmaniasisExpert Opin Emerg Drugs200914339541019708817
   PubMed Web of Science ®Google Scholar
• van GriensvenJBalasegaramMMeheusFAlvarJLynenLBoelaertMCombination therapy for visceral leishmaniasisLancet Infect Dis201010318419420185097
   PubMed Web of Science ®Google Scholar
• SoniPPrasadNKhandelwalKUnresponsive cutaneous leishmaniasis and HIV co-infection: report of three casesIndian J Dermatol Venereol Leprol2011772251
   Web of Science ®Google Scholar
• GuimaraesLHMachadoPRLagoELAtypical manifestations of tegumentary leishmaniasis in a transmission area of Leishmania braziliensis in the state of Bahia, BrazilTrans R Soc Trop Med Hyg2009103771271519481233
   PubMed Web of Science ®Google Scholar
• LindosoJABarbosaRNPosada-VergaraMPUnusual manifestations of tegumentary leishmaniasis in AIDS patients from the New WorldBr J Dermatol2009160231131819187345
   PubMed Web of Science ®Google Scholar
• GuerraJACoelhoLIPereiraFRAmerican tegumentary leishmaniasis and HIV-AIDS association in a tertiary care center in the Brazilian AmazonAm J Trop Med Hyg201185352452721896816
   PubMed Web of Science ®Google Scholar
• Gomes-SilvaAde Cassia BittarRDos Santos NogueiraRCan interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection?Clin Exp Immunol2007149344044417614975
   PubMed Web of Science ®Google Scholar
• Ribeiro de JesusALunaTPacheco de AlmeidaRMachadoPRCarvalhoEMPentoxifylline down modulate in vitro T cell responses and attenuate pathology in Leishmania and HTLV-I infectionsInt Immunopharmacol20088101344135318687297
   PubMed Web of Science ®Google Scholar
• MachadoPRLessaHLessaMOral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasisClin Infect Dis200744678879317304449
   PubMed Web of Science ®Google Scholar
• Miranda-VerasteguiCTullianoGGyorkosTWFirst-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimonyPLoS Negl Trop Dis200937e49119636365
   PubMed Web of Science ®Google Scholar
• LessaHAMachadoPLimaFSuccessful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimonyAm J Trop Med Hyg2001652878911508396
   PubMed Web of Science ®Google Scholar
• ArevaloIWardBMillerRSuccessful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulatorClin Infect Dis200133111847185111692295
   PubMed Web of Science ®Google Scholar
• FalcoffETarantoNJRemondeguiCEClinical healing of antimony-resistant cutaneous or mucocutaneous leishmaniasis following the combined administration of interferon-gamma and pentavalent antimonial compoundsTrans R Soc Trop Med Hyg199488195978154019
   PubMed Web of Science ®Google Scholar
• AlmeidaRD’OliveiraAJrMachadoPRandomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous LeishmaniasisJ Infect Dis199918051735173710515844
   PubMed Web of Science ®Google Scholar
• ColerRNGotoYBogatzkiLRamanVReedSGLeish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cellsInfect Immun20077594648465417606603
   PubMed Web of Science ®Google Scholar
• BadaroRLoboIMunosAImmunotherapy for drug-refractory mucosal leishmaniasisJ Infect Dis200619481151115916991091
   PubMed Web of Science ®Google Scholar
• ConvitJUlrichMZerpaOImmunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990–1999Trans R Soc Trop Med Hyg200397446947215259484
   PubMed Web of Science ®Google Scholar
• GonzalezUPinartMRengifo-PardoMMacayaAAlvarJTweedJAInterventions for American cutaneous and mucocutaneous leishmaniasisCochrane Database Syst Rev20092CD00483419370612
   PubMed Web of Science ®Google Scholar
• TiumanTSSantosAOUeda-NakamuraTFilhoBPNakamuraCVRecent advances in leishmaniasis treatmentInt J Infect Dis2011158e525e53221605997
   PubMed Web of Science ®Google Scholar
• MiguelDCYokoyama-YasunakaJKUlianaSRTamoxifen is effective in the treatment of Leishmania amazonensis infections in micePLoS Negl Trop Dis200826e24918545685
   PubMed Web of Science ®Google Scholar